Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals (KALV) presented new data for sebetralstat in treating hereditary angioedema (HAE) attacks at the AAAAI/WAO 2025 Joint Congress. The KONFIDENT-S study showed promising results for laryngeal HAE attacks, with patients achieving:
- Median treatment time of 11.5 minutes after attack onset
- Median symptom relief time of 1.27 hours
- 96% effectiveness with single dose
- No difficulty swallowing tablets reported
For adolescent patients, pooled analysis from KONFIDENT/KONFIDENT-S studies (149 attacks) demonstrated:
- Median treatment time of 4 minutes vs. traditional 3+ hours
- Safety and efficacy comparable to adults
- No serious adverse events
If approved, sebetralstat would become the first oral on-demand treatment for HAE attacks, potentially transforming HAE management, particularly for vulnerable populations like adolescents and those experiencing laryngeal attacks.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced its participation in two major upcoming investor conferences. The company will engage in fireside chat presentations at the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025, at 1:10 p.m. ET, and at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10, 2025, at 8:00 a.m. ET.
Both presentations will be accessible through live webcasts on KalVista's website (www.kalvista.com). The company will maintain audio archives of the presentations on their website for a 30-day period following the events.
KalVista Pharmaceuticals (Nasdaq: KALV) has announced the acceptance of six abstracts for presentation at the AAAAI/WAO 2025 Joint Congress in San Diego from February 28–March 3, 2025. The presentations focus on sebetralstat and hereditary angioedema (HAE) treatment research.
Three poster presentations on February 28 will address barriers to HAE treatment in Italian patients, burden of injectable treatments in adolescents, and delays in on-demand treatment across healthcare systems. Two late-breaking posters on March 1 will present findings on HAE with normal C1INH diagnoses and sebetralstat's effectiveness for laryngeal HAE attacks from the KONFIDENT-S study.
An oral presentation on March 1 will discuss sebetralstat's use for on-demand HAE attack treatment in adolescents, analyzing pooled data from KONFIDENT and KONFIDENT-S studies. All presentation materials will be available on KalVista's website under Publications.
KalVista Pharmaceuticals (NASDAQ: KALV) presented new data for sebetralstat at the WSAAI 2025 Annual Meeting. Key findings reveal that 40% of HAE patients on long-term prophylaxis (LTP) experience prescription refill gaps, with over half discontinuing treatment. The KONFIDENT-S study showed patients on LTP average 1.7 HAE attacks per month, with symptom relief achieved in a median of 1.3 hours using sebetralstat.
The data demonstrated sebetralstat's effectiveness as an on-demand treatment regardless of LTP therapy type, including all-oral regimens. Patients treated attacks early (median 6 minutes), and the drug was well-tolerated across different LTP mechanisms. For patients specifically on berotralstat, sebetralstat treated 178 attacks (mean 1.8 attacks/month) with early treatment (median 20 minutes) and symptom relief (median 1.3 hours).
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the granting of inducement stock options to 52 newly-hired employees. The compensation committee approved options to purchase a total of 261,000 shares of KalVista common stock on February 3, 2025. The exercise price matches the closing price of KalVista stock on the grant date.
The vesting schedule includes 25% of options vesting after one year, with the remaining options vesting in equal monthly installments over the following three years, contingent on continued employment. The options have a 10-year term and are governed by KalVista's Inducement Equity Incentive Plan and individual stock option agreements, in compliance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) has achieved two significant milestones in Japan for sebetralstat, its investigational oral treatment for hereditary angioedema (HAE) attacks. The company received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare and submitted a New Drug Application (NDA) for the medication.
If approved, sebetralstat would become the first oral on-demand treatment for HAE in Japan, targeting adults and adolescents aged 12 years and older. The drug is a novel plasma kallikrein inhibitor, and its NDA submission is supported by data from the KONFIDENT phase 3 clinical trial and ongoing KONFIDENT-S open-label extension trial.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced new inducement grants for recently hired employees. On January 2, 2025, nine new employees were granted options to purchase a total of 61,000 shares of KalVista common stock. Additionally, on January 6, 2025, one new employee received options to purchase 50,000 shares.
The options' exercise price equals the closing price of KalVista stock on their respective grant dates. The vesting schedule includes 25% after one year, with the remaining portions vesting monthly over three years, contingent on continued employment. All options have a 10-year term and are governed by KalVista's Amended and Restated 2021 Equity Inducement Plan, granted under Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Jeb Ledell as Chief Operating Officer. Ledell brings over 20 years of biotechnology industry leadership experience, joining from AVEO Oncology. His previous roles include COO positions at Enzyvant Therapeutics, where he contributed to RETHYMIC®'s FDA approval, and leadership positions at Compass Therapeutics and Horizon Discovery Group.
As part of his employment agreement, Ledell received inducement options for 100,000 shares of Common Stock, with an exercise price equal to the closing price on December 16, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 fiscal 2024 results and provided updates on sebetralstat, its investigational oral treatment for hereditary angioedema (HAE) attacks. The FDA accepted the New Drug Application with a PDUFA date of June 17, 2025. The company submitted Marketing Authorization Applications in multiple countries.
Financial highlights include pro forma cash and equivalents of $292.2 million, providing runway into second half 2027. The company raised $160 million through synthetic royalty financing and equity offerings. Q2 showed no revenue, R&D expenses of $16.6 million (down from $19.1 million), and G&A expenses of $29.2 million (up from $10.7 million) primarily due to pre-commercial activities.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to five newly-hired employees. The compensation committee approved options to purchase 36,000 shares of common stock at an exercise price of $10.27 per share, matching the closing price on December 2, 2024. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years, contingent on continued employment. These 10-year term options were granted under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
